This article through to the targeted TNF alpha, targeted IL/17, targeted IL-12/23, targeted, targeted IL-6 and IL-1 targeting leukocyte differentiation antigen anti-rheumatism medicine on the clinical trials of summary, clear of advantages and disadvantages of different types of drugs in the treatment process, help us to determine the optimal dosage regimen in the future (Table 2). This evidence concerns the gene IL1A and rheumatic disorder.